Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

LESSONS LEARNED. The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological ratio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Clinical Trial Results
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738301/
https://ncbi.nlm.nih.gov/pubmed/31152080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0331
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki